🚀 VC round data is live in beta, check it out!
Stenocare Valuation Multiples
Discover revenue and EBITDA valuation multiples for Stenocare and similar public comparables like Acurx Pharmaceuticals, FibroBiologics, Akari Therapeutics, MetaVia and more.
Stenocare Overview
About Stenocare
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The Company’s business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The Company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway. It has an indoor production facility for the cultivation and production of medical cannabis at Randers, Denmark.
Founded
2017
HQ
Employees
8
Website
Sectors
Financials (FY)
EV
$7M
Stenocare Financials
Stenocare reported last fiscal year revenue of $1M and negative EBITDA of ($262K).
In the same fiscal year, Stenocare generated $193K in gross profit, ($262K) in EBITDA losses, and had net loss of ($376K).
Stenocare P&L
In the most recent fiscal year, Stenocare reported revenue of $1M and EBITDA of ($262K).
Stenocare expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $193K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 17% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($262K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (24%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (25%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($376K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (34%) | XXX | XXX | XXX |
| Net Debt | — | — | $187K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Stenocare Stock Performance
Stenocare has current market cap of $7M, and enterprise value of $7M.
Market Cap Evolution
Stenocare's stock price is $0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7M | $7M | 0.0% | XXX | XXX | XXX | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialStenocare Valuation Multiples
Stenocare trades at 6.3x EV/Revenue multiple, and (26.7x) EV/EBITDA.
Stenocare Financial Valuation Multiples
As of April 19, 2026, Stenocare has market cap of $7M and EV of $7M.
Equity research analysts estimate Stenocare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stenocare has a P/E ratio of (18.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV (current) | $7M | XXX | $7M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (26.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (25.0x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 36.3x | XXX | XXX | XXX |
| P/E | — | XXX | (18.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (6.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Stenocare Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Stenocare Margins & Growth Rates
Stenocare's revenue in the last fiscal year grew by 215%.
Stenocare's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Stenocare Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 215% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (24%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (93%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 43% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Stenocare Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Stenocare | XXX | XXX | XXX | XXX | XXX | XXX |
| Acurx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| FibroBiologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Akari Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| MetaVia | XXX | XXX | XXX | XXX | XXX | XXX |
| Gelteq | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stenocare M&A Activity
Stenocare acquired XXX companies to date.
Last acquisition by Stenocare was on XXXXXXXX, XXXXX. Stenocare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Stenocare
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialStenocare Investment Activity
Stenocare invested in XXX companies to date.
Stenocare made its latest investment on XXXXXXXX, XXXXX. Stenocare invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Stenocare
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Stenocare
| When was Stenocare founded? | Stenocare was founded in 2017. |
| Where is Stenocare headquartered? | Stenocare is headquartered in Denmark. |
| How many employees does Stenocare have? | As of today, Stenocare has over 8 employees. |
| Is Stenocare publicly listed? | Yes, Stenocare is a public company listed on Nasdaq Copenhagen. |
| What is the stock symbol of Stenocare? | Stenocare trades under STENO ticker. |
| When did Stenocare go public? | Stenocare went public in 2020. |
| Who are competitors of Stenocare? | Stenocare main competitors are Acurx Pharmaceuticals, FibroBiologics, Akari Therapeutics, MetaVia. |
| What is the current market cap of Stenocare? | Stenocare's current market cap is $7M. |
| What is the current revenue of Stenocare? | Stenocare's last fiscal year revenue is $1M. |
| What is the current EV/Revenue multiple of Stenocare? | Current revenue multiple of Stenocare is 6.3x. |
| Is Stenocare profitable? | No, Stenocare is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.